Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 24, 2025 04:05 ET | Source: Castle Biosciences, Inc.

New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference

Castle is presenting data on DecisionDx®-Melanoma and its pipeline atopic dermatitis (AD) test at the 25th Annual Fall Clinical Dermatology Conference.
October 08, 2025 05:12 ET | Source: Research and Markets

Cutaneous Squamous Cell Carcinoma Market Forecast Report 2025-2035, with Focus on Regeneron Pharmaceuticals, Sanofi, Merck & Co., Checkpoint Therapeutics, Incyte, and Sirnaomics

Dublin, Oct. 08, 2025 (GLOBE NEWSWIRE) -- The "Cutaneous Squamous Cell Carcinoma Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" report has...
August 25, 2025 07:00 ET | Source: Castle Biosciences, Inc.

New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma

Castle announced the publication of two new studies related to its DecisionDx-SCC test for patients with high-risk cutaneous squamous cell carcinoma.
August 18, 2025 10:15 ET | Source: Affidea Group; Skin Analytics

Affidea partners with Skin Analytics to improve access to skin cancer assessment across Europe using AI technology

THE HAGUE, The Netherlands, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Affidea, a leading pan-European provider of community-based polyclinics, advanced diagnostics, and multi-specialist care, including...
August 08, 2025 08:30 ET | Source: InvestorBrandNetwork (IBN)

NetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin Cancer

AUSTIN, Texas, Aug. 08, 2025 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth...
August 04, 2025 16:05 ET | Source: Castle Biosciences, Inc.

Castle Biosciences Reports Second Quarter 2025 Results

Delivered Q2 2025 revenue of $86 million Q2 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 33% over Q2 2024 Raising full-year 2025 revenue...
July 31, 2025 09:20 ET | Source: SNS Insider pvt ltd

Global Skin Cancer Treatment Market Size to Reach USD 19.27 Billion by 2032, Driven by Rising Melanoma Cases and Advancements in Immunotherapy | SNS Insider

Austin, July 31, 2025 (GLOBE NEWSWIRE) -- Skin Cancer Treatment Market Size & Growth Analysis: According to SNS Insider, the Skin Cancer Treatment Market was valued at USD 10.87 billion in 2024...
July 23, 2025 07:00 ET | Source: Castle Biosciences, Inc.

FDA Grants Breakthrough Device Designation to Castle Biosciences’ DecisionDx®-Melanoma Test

Castle announced that its DecisionDx®-Melanoma test has been granted Breakthrough Device designation from the U.S. Food and Drug Administration (FDA).
May 07, 2025 07:00 ET | Source: Castle Biosciences, Inc.

Castle Biosciences Celebrates Skin Cancer Awareness Month

Castle continues its ongoing patient advocacy partnerships and highlights cancer journey to drive education and awareness for Skin Cancer Awareness Month
April 28, 2025 09:18 ET | Source: VITAS Healthcare

VIDEO: California Firefighter ‘Living the Best of These Last Months’ on Hospice Care

In a new video by VITAS Healthcare, hospice patient Jim Forrester and his wife share the difference that hospice care made in their lives.